Previous studies have sought to classify bladder cancer(BLCA)into different molecular subtypes to understand its pathogenic pathways and uncover specific treatments.1 These subtypes,often based on genetic,transcriptom...Previous studies have sought to classify bladder cancer(BLCA)into different molecular subtypes to understand its pathogenic pathways and uncover specific treatments.1 These subtypes,often based on genetic,transcriptomic,or proteomic profiles,aim to stratify patients for precision medicine and improve therapeutic outcomes.Despite these efforts,such classifications have rarely been applied in clinical practice due to challenges in standardization,reproducibility,and limited translational studies validating their utility.1 The treatment of BLCA predominantly relies on surgery,often combined with chemotherapy,immunotherapy,targeted therapy,or antibody-drug conjugates.Radical cystectomy remains the cornerstone for muscle-invasive bladder cancer(MIBC),while transurethral resection and intravesical therapy are common for non-muscle-invasive bladder cancer(NMIBC).2 However,the choice of its treatment modality still depends specifically on whether the disease is NMIBC or MIBC,rather than on the various molecular subtype classifications.3 Bridging the gap between molecular research and clinical application remains a significant challenge,highlighting the need for robust biomarker validation and the development of treatment algorithms that incorporate these subtypes to better guide personalized therapy.展开更多
Bladder cancer(BCa)is the ninth most frequently diagnosed tumor worldwide,and smoking remains a major risk faaor.BCa is divided into nonmuscle invasive bladder cancer(NMIBC)and muscle invasive bladder cancer(MIBC).1 N...Bladder cancer(BCa)is the ninth most frequently diagnosed tumor worldwide,and smoking remains a major risk faaor.BCa is divided into nonmuscle invasive bladder cancer(NMIBC)and muscle invasive bladder cancer(MIBC).1 NMIBC accounts for 70-80% of all BCa cases,its recurrence rate is high,and 20-30% of NMIBC patients progress to MIBC.展开更多
基金supported by the National Natural Science Foundation of China(No.82273065)Fundamental Research Funds for the Central Universities(China)(No.2042022dx0003)+1 种基金Research Fund of Zhongnan Hospital of Wuhan University(Wuhan,China)(No.YYXKNLJS2024001,PTPP2024001)The funders played no role in the study design,data collection and analysis,decision to publish,or preparation of the manuscript.
文摘Previous studies have sought to classify bladder cancer(BLCA)into different molecular subtypes to understand its pathogenic pathways and uncover specific treatments.1 These subtypes,often based on genetic,transcriptomic,or proteomic profiles,aim to stratify patients for precision medicine and improve therapeutic outcomes.Despite these efforts,such classifications have rarely been applied in clinical practice due to challenges in standardization,reproducibility,and limited translational studies validating their utility.1 The treatment of BLCA predominantly relies on surgery,often combined with chemotherapy,immunotherapy,targeted therapy,or antibody-drug conjugates.Radical cystectomy remains the cornerstone for muscle-invasive bladder cancer(MIBC),while transurethral resection and intravesical therapy are common for non-muscle-invasive bladder cancer(NMIBC).2 However,the choice of its treatment modality still depends specifically on whether the disease is NMIBC or MIBC,rather than on the various molecular subtype classifications.3 Bridging the gap between molecular research and clinical application remains a significant challenge,highlighting the need for robust biomarker validation and the development of treatment algorithms that incorporate these subtypes to better guide personalized therapy.
基金supported in part by grants from the Fundamental Research Funds for the Central Universities(2042018kf1040)the Chinese Central Special Fund for Local Science and Technology Development of Hubei Province(2018ZYYD023)+1 种基金the Science and Technology Department of Hubei Province Key Project(2018ACA159)the Wuhan Science and Technology Bureau Key Project(2018061005132294).
文摘Bladder cancer(BCa)is the ninth most frequently diagnosed tumor worldwide,and smoking remains a major risk faaor.BCa is divided into nonmuscle invasive bladder cancer(NMIBC)and muscle invasive bladder cancer(MIBC).1 NMIBC accounts for 70-80% of all BCa cases,its recurrence rate is high,and 20-30% of NMIBC patients progress to MIBC.
